Spironolactone use does not increase the risk of female breast cancer recurrence: A retrospective analysis.

[1]  M. Lacouture,et al.  Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies , 2018, Breast Cancer Research and Treatment.

[2]  K. Egan,et al.  Interactions between Alcohol Consumption and Adjuvant Hormone Therapy in Relation to Breast Cancer-Free Survival , 2018, Journal of breast cancer.

[3]  A. Brufsky,et al.  Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance. , 2018, The oncologist.

[4]  F. Zannad,et al.  Spironolactone in cardiovascular disease: an expanding universe? , 2017, F1000Research.

[5]  W. James,et al.  Spironolactone for the treatment of acne in women, a retrospective study of 110 patients☆☆☆★ , 2017, International journal of women's dermatology.

[6]  A. Thompson,et al.  Spironolactone use and risk of incident cancers: a retrospective, matched cohort study , 2016, British journal of clinical pharmacology.

[7]  Per Karlsson,et al.  Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Fabrizio Stracci,et al.  Validity of ICD-9-CM codes for breast, lung and colorectal cancers in three Italian administrative healthcare databases: a diagnostic accuracy study protocol , 2016, BMJ Open.

[9]  J. Dains,et al.  Hormone Replacement Therapy: An Increased Risk of Recurrence and Mortality for Breast Cancer Patients? , 2015, Journal of the advanced practitioner in oncology.

[10]  R. Biggar,et al.  Spironolactone use and the risk of breast and gynecologic cancers. , 2013, Cancer epidemiology.

[11]  M. Terry,et al.  Alcohol Intake and Breast Cancer Risk: Weighing the Overall Evidence , 2013, Current Breast Cancer Reports.

[12]  X. Shu,et al.  Postdiagnosis Alcohol Consumption and Breast Cancer Prognosis in the After Breast Cancer Pooling Project , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[13]  A. Goldhirsch,et al.  Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  A. Thompson,et al.  Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study , 2012, BMJ : British Medical Journal.

[15]  R. Sinclair,et al.  Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. , 2010, Dermatologic clinics.

[16]  Edgar Erdfelder,et al.  G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences , 2007, Behavior research methods.

[17]  H. Quan,et al.  Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.

[18]  J. Emer,et al.  International Journal of Women's Health Dovepress Female Pattern Alopecia: Current Perspectives , 2022 .